Clinical trial
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
NCT02430714 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
- Lead sponsor
- Eisai Co., Ltd.
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 20, 2015
- Completion date
- November 6, 2016
- Enrollment
- 629 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.